Thursday 01 October 2026
—
A Mother’s Fight for Earlier Diagnosis
When Jesy Nelson first learned that her twin daughters, Ocean Jade and Story Monroe, were born with spinal muscular atrophy (SMA), the reality hit hard. In a candid moment captured by the media, she spoke of the stark prognosis: “they are unlikely to ever be able to walk.” For a mother already juggling the joys of twins, the news was both a celebration of life and a stark warning about a condition that steals motor skills before a child can even sit unaided.
Nelson’s personal journey quickly morphed into a public crusade. Leveraging her platform as a former Little Mix star, she began to share the twins’ story, pleading for systemic change. Her advocacy resonated with families across the UK who have watched loved ones battle SMA without early detection. The result? A nationwide trial that will see every newborn in England screened for SMA as part of the routine heel‑prick test, starting this very week.
The New Screening Programme Takes Shape
The NHS England screening programme, which already checks babies for ten rare conditions, is expanding to include SMA from Thursday. Government statistics reveal that SMA affects roughly one in every 10,000 babies nationwide, with an estimated 60‑70 infants born with the condition each year in England alone.
Medical research underscores the urgency of early intervention. Treatments for SMA demonstrate the highest efficacy when administered before any physical symptoms appear. Preliminary modelling suggests that universal screening across England could prevent around three early infant deaths annually, spare two babies from permanent ventilation, and enable roughly 37 infants to lead largely normal lives.
The rollout is being staged deliberately. A new laboratory will join the screening network roughly every two months, a process that will continue until October 2027. The first wave launches in Birmingham on Thursday, followed by Manchester, South West Thames, South East Thames, Great Ormond Street Hospital and Sheffield. Six additional sites—Portsmouth, Oxford, Cambridge, Bristol, Leeds and Liverpool—will be added later. The ultimate aim is that every baby born in England will be offered SMA screening by spring 2028.
Voices from the Frontlines
Louise Parkes, chief executive of Great Ormond Street Hospital Charity, describes the moment as “a hugely important moment for babies and families.” She stresses that the national rollout means more infants will be diagnosed before symptoms appear, giving them the best chance to access effective treatment before irreversible damage occurs. “This change follows years of tireless campaigning by the SMA community and shows what can be achieved when advances in treatment are matched by earlier diagnosis,” she adds.
Andy Fletcher, chief executive of Muscular Dystrophy UK, warns that the progress in England must not leave Wales and Northern Ireland behind. Scotland has already introduced screening, and he argues that a “postcode lottery” is simply unacceptable. “Every baby matters,” he says. “Babies with SMA in Wales and Northern Ireland deserve the same chance of early diagnosis.”
Dr Harrison Carter, director of screening at NHS England, calls the initiative “a potentially life‑changing moment for parents in Birmingham, whose babies will be the first to benefit from spinal muscular atrophy screening on the NHS.” He explains that catching the condition before symptoms develop gives children the best opportunity to benefit from NHS treatments, helping them reach milestones such as sitting, walking and breathing independently.
Clare Livingstone, head of professional policy and practice at the Royal College of Medicine, highlights the role of midwives. “Midwives play an important role in newborn screening, supporting parents to understand the tests being offered and why,” she notes. “Adding SMA to the newborn screening is going to make a huge difference.”
Giles Lomax, chief executive of SMA UK, reflects on the community’s perseverance. “After years of campaigning by the community, it is incredibly powerful to see this work becoming a reality,” he says, thanking laboratory staff for their tireless efforts. “Thousands of babies each year will have the opportunity to be diagnosed earlier and access life‑changing treatment before irreversible damage occurs.”
From Local Launch to Nationwide Coverage
The first phase of the rollout is already under way in Birmingham, a city that will become the pilot site for SMA screening. Health officials there are preparing staff and logistics to ensure that every newborn in the area is offered the test without delay. The subsequent additions of Manchester, the Thames regions and the Great Ormond Street Hospital site are designed to spread expertise across the country, creating a network that can be scaled up efficiently.
The staggered approach allows the NHS to gather real‑world data on how quickly infants identified with SMA are referred to specialist services. This evidence will be crucial when the UK National Screening Committee evaluates whether to make SMA screening a permanent fixture of the routine programme.
For families like Jesy Nelson’s, the new system promises a future where early diagnosis replaces uncertainty. While the twins’ journey will still involve challenges, the prospect of treatment beginning before any muscle weakness appears offers a glimmer of hope that their condition may not define their lives.
Why it Matters
The introduction of SMA screening across England marks a turning point not only for medical science but for the countless families who have long campaigned for earlier detection. It reflects a broader commitment to ensuring that no child is left behind because of geography or timing, and it demonstrates how public advocacy can shape health policy. By catching spinal muscular atrophy at its earliest stages, the NHS stands to prevent needless loss of life, reduce the need for lifelong ventilation, and enable more children to reach developmental milestones that were once out of reach. This shift also highlights the importance of a responsive screening system that can adapt quickly as new treatments emerge, setting a precedent for other rare conditions that may benefit from similar early‑intervention strategies. The ripple effect of this change will be felt far beyond the first babies screened in Birmingham, offering a blueprint for equitable, compassionate healthcare across the United Kingdom.
